Protein kinases are major drug targets, but the development of highly-selective inhibitors has 16 been challenging due to the similarity of their active sites. The observation of distinct structural 17 states of the fully-conserved Asp-Phe-Gly (DFG) loop has put the concept of conformational 18 selection for the DFG-state at the center of kinase drug discovery. Recently, it was shown that
Introduction 39
Protein kinases have become the number one drug target of the 21 th century (Cohen, 2002;  248 to the three-step binding scheme ( Figure 5I ). Although global fitting of the binding and dissociation 249 kinetics in KinTek Explorer delivered a value for '& , evaluation of the kinetic scheme with respect 250 to the time traces exposes that '& is not well determined from our experiments. We therefore 251 designed a double-jump experiment to populate the AurAout:D state followed by dissociation to 252 obtain more accurate information on '& . Our stopped-flow machine lacks the capability to 253 perform double mixing. Therefore, the double-jump experiment was performed using a Creoptix 254 WAVE instrument. This label-free methodology uses waveguide interferometry to detect refractive 255 index changes due to alteration in surface mass in a vein similar to Surface Plasmon Resonance 256 (SPR). It is an orthogonal technique that sidesteps notable issues associated with fluorescence 257 methods (e.g., photobleaching and inner-filter effects). In short, after immobilizing Aurora A on a 258 WAVEchip, a high concentration of Danusertib was injected for a short, variable period of time, 
262
We want to discuss a few additional kinetic features. First, the observed rate constant 263 measured in the dilution experiment ( Figure 5E , '/ = (3.2 ± 0.3) ´ 10 -4 s -1 ) is slower than '/ 264 from the global fit ( '/ = (7.1 ± 0.5) ´ 10 -4 s -1 ), which might seem counterintuitive. The observed 265 rate constant was verified by an additional dilution experiment using Creoptix WAVE ( '/ = (2 ± 266 0.6) ´ 10 -4 s -1 , Figure 5 
275
Our results illuminate trivial but profound principles of binding affinity and lifetime of 276 drug/target complexes: a conformational selection mechanism always weakens the overall 277 inhibitor affinity, while an induced-fit step tightens the affinity depending on how far-shifted the 278 equilibrium in the enzyme/drug complex is (Equations 2, 3 and 4). For DFG-out binders (e.g.,
279
Danusertib and Gleevec), the DFG-in and -out equilibrium weakens the overall affinity 1.6-fold; 280 however, the conformational change after drug binding results in a four orders of magnitude 281 tighter binding for Danusertib and is the sole reason for its high affinity to Aurora A compared to 282 Gleevec. The dissociation constants for the bimolecular binding step & is very similar for both 283 inhibitors. Finally, the lifetime of Danusertib on the target is very long because of the very slow 284 conformational dynamics within the Aurora A/Danusertib complex ( '/ = (7.1 ± 0.5) ´ 10 -4 s -1 ).
286
Kinetics of AT9283 binding to Aurora A -a surprise 287 We chose AT9283 as a third inhibitor to characterize the binding mechanism because it has been 288 described as a DFG-in binder based on a crystal structure of AT9283 bound to Aurora A (PDB 289 2W1G, (Howard et al., 2009) ). We, therefore, anticipated that in its binding kinetics one can now 290 detect the DFG-out to DFG-in switch. Rapid kinetic experiments of binding AT9283 to Aurora A 291 at 25 °C resulted in biphasic traces and both processes showed an increase in fluorescence over 292 time ( Figure 7A ). The #$% for the faster phase ( & ) was linearly dependent on drug concentration 293 reflecting the binding step ( Figure 7B ) and #$% for the slower phase ( / ) has a limiting value of 294 0.8 ± 0.2 s -1 and is attributed to an induced-fit step ( Figure 7C ). For the conformational selection 295 step (i.e., DFG-out to DFG-in), a decrease in fluorescence is expected because for the reverse 296 flip observed in the Gleevec and Danusertib experiments, a fluorescence increase was seen 297 ( Figure 3A and Figure 5-figure supplement 1A) . However, we could not find any condition (e.g.,
298
by varying temperature and ligand concentrations) where such a phase could be observed. 
314
Finally, the 10-fold difference between the '/ from the global fit ( Figure 7H 
318

Crystal structures of AT9283 bound to Aurora A buttress new binding model
319
In an effort to structurally verify our model we solved a crystal structure of Aurora A with AT9283 320 bound and indeed observed the DFG-out conformation (PDB 6CPG, Figure 9B and 322 (Howard et al., 2009 ). Our structure was obtained by co-crystalizing Aurora A with AT9283 and a 323 monobody that binds to the same site as the natural allosteric activator TPX2 ( Figure 9B ). Binding 324 of this monobody shifts Aurora A into an inactive conformation, with the DFG-loop in the out 325 conformation. This new structure underscores the plasticity of Aurora A kinase and the ability of 326 AT9283 to bind to a DFG-out state, in addition to the previously reported DFG-in state.
327
Thus, our structural and kinetic data together support that AT9283 can bind to both DFG-328 in and DFG-out state of Aurora A, and emphasizes the need for caution when interpreting single 329 X-ray structures.
331
Inhibitors take advantage of built-in dynamics for ATP binding
332
We finally compared the binding kinetics of the ATP-competitive inhibitors described above with 
336
Shaffer, & Adams, 2000) . The binding of mant-ATP to Aurora A showed biphasic kinetic traces 337 ( Figure 10A ) that describe the physical binding step (i.e., linear dependence on mant-ATP 338 concentration; Figure 10B ) and the induced-fit step ( Figure 10C ). The observed rate constant 339 11 approaches a maximum value defined by the sum of / + '/ ( Figure 10C ) and the intercept can 340 be estimated to be '/ and is consistent with the value obtained from the #--experiment (Figure
341
10D). We find that mant-ATP can bind to both the DFG-in or -out conformations, consistent with 342 our nucleotide-bound crystal structures ( Figure 1A -D) and recent single-molecule fluorescence 343 spectroscopy data that indicates that nucleotide binding does not significantly affects this 344 equilibrium (Gilburt et al., 2017) . To confirm the model, the kinetic data were globally fit to a two-345 step binding mechanism ( Figure 10H , G). The calculated , from the corresponding microscopic 346 rate constants ( Figure 10H ) is comparable with experimental macroscopic , obtained from a 347 titration experiment ( Figure 10E , F).
348
The presence of an induced-fit step for the natural substrate ATP suggests that such 349 conformational change after ligand binding is a built-in property of the enzyme. In other words,
350
inhibitors take advantage of the inherent plasticity of the enzyme that is required for its activity 351 and regulation. The main difference between ATP and inhibitor binding is the rate constant for the 352 reverse induced-fit step ( '/ ). In the case of ATP, this rate is much faster and, therefore, does 
361
Discussion 362
Characterizing the detailed kinetic mechanisms of drug binding is not just an academic exercise 363 but delivers fundamental knowledge for developing selective inhibitors with high affinity. An 364 induced-fit step turns out to be key for all tight-binding inhibitors studied. From our results on 365 Aurora A kinase presented here and earlier data on Tyrosine-kinases (Agafonov et al., 2014;  366 Wilson et al., 2015) , we propose that this is a general mechanism for different kinases and multiple 367 inhibitors, thereby providing a platform for future computational and experimental efforts in rational 368 drug design.
369
The "use" of a far-shifted induced-fit step for a promising drug is logical for the following 370 reasons: (i) it increases the affinity for the drug by this coupled equilibrium, (ii) it prolongs the 371 residence time of the drug on the target due to the often slow reverse rate, (iii) it is specific for 372 each drug as it happens after the drug binding, and (iv) it can add selectivity for the targets 12 because it likely involves residues more remote from the active site. An increased drug residence 374 time has significant pharmacological advantages as it can lead to a prolonged biological effect, a 375 decrease of side effects, and a lower risk of metabolic drug modification. Such inhibitors have 376 long been described as slow tight-binding inhibitors (Copeland, 2016; Copeland, Pompliano, & 
377
Meek, 2006). The concept of the advantageous roles of induced-fit steps is based on simple 378 thermodynamics and protein flexibility, and is, therefore, likely of relevance for drug design to 379 other targets outside of the kinome.
380
Additionally, our data provides unique insight into the extensively discussed DFG flip. 
394
Our results exemplify why rational drug design is so challenging. The characterization of 395 the complete free-energy landscape of drug binding is needed, which will require more 396 sophisticated computational approaches guided by experimental data such as provided in our 
493
The data collection and refinement statistics are given in 
504
An interscan delay of 1.5 s was used with 5,000 scans per transients, giving rise to a total 505 acquisition time of 2.5 h per spectrum. To remove background signal from the probe and avoid 506 baseline distortions, data acquisition was started after a ~100 µs delay (using the "delacq" macro) 507 and appropriate shifting of the data followed by backward linear prediction was performed. The 508 16 data were apodized with an exponential filter (2.5 Hz line broadening) and zero-filled before 509 Fourier transform. To improve the signal-to-noise ratio several data sets were recorded 510 consecutively and, provided that the sample remained stable, added together after processing 511 (two for apo Aurora A, four for Aurora A + AMPPCP, and five for W277L + AMPPCP, respectively). 
548
Under the rapid equilibrium approximation, the binding and dissociation steps of Gleevec 549 to Aurora A are fast compared to conformational selection, therefore the value of ( and '( can 613 614
Conformational selection mechanism, followed by inhibitor binding to both DFG-in and -out state,
615
but an induced-fit step only occurs in the DFG-in state:
617
Equation 5 618 619
The uncertainties in the calculated dissociation constant parameter using the equations above 620 are obtained using standard error propagation. Gleevec (labeled as G) binding scheme to Aurora A corresponds to a two-step binding mechanism: conformational selection followed by the physical binding step. The corresponding microscopic rate constants obtained from the global fit and calculated overall equilibrium and dissociation constants are shown. Fluorescence traces are the average of at least five replicate measurements (n > 5), and error bars and uncertainties given in C-G denote the (propagated) standard deviation in the fitted parameter. In the first step of the double jump, Danusertib is incubated with surface-immobilized Aurora A kinase before washing with buffer alone initiates dissociation in a second step. All traces show a single exponential decay with an observed rate constant of 6 s -1 and its amplitude increases with longer incubation time as more AurA out :D is formed. (C) Dilution of the Aurora A/Danusertib complex formed after 1 hour incubation. The slow dissociation of Aurora A/Danusertib (limited by k -3 ) was measured by Creoptix WAVE waveguide interferometry and fitted to a single exponential with a value of k -3 = (2 ± 0.6) x 10 -4 s -1 . (D) Representative selection of emission spectra obtained after the addition of increasing concentrations of Danusertib (0 -11.25 nM from dark to light blue) to Aurora A (excitation at 295 nm). Plot of the increase in fluorescence intensity at 368 nm versus Danusertib concentration yields a K D value of 0.4 ± 0.1 nM determined by fitting the data to Equation 6. Fluorescence trace in A is the average of five replicate measurements (n = 5), and the uncertainties given in D denotes the standard deviation in the fitted parameter. Figure 6 . Global fits of Danusertib binding and dissociation kinetics to Aurora A at 25 °C. Binding kinetics was monitored by stopped-flow fluorescence for different concentrations of Danusertib (indicated) to 0.5 μM Aurora A, and dissociation kinetics (k obs,off ) by Creoptix and fluorimeter (see Figure  5 ). Fluorescence traces are the average of at least five replicate measurements (n > 5). Global fitting was performed using the KinTek Explorer software using the model shown in Figure 5I . (H) Binding scheme for AT9283 (labeled AT) highlighting a four-steps binding mechanism, that contains binding to two different states, a conformational selection mechanism and an induced-fit step. Kinetic constants shown in H were determined from global fitting (see Figure 8 ). Fluorescence traces are the average of at least five replicate measurements (n > 5), and error bars and uncertainties given in B,C,G and H denote the (propagated) standard deviation in the fitted parameter. Figure 8 . Global fits of AT9283 binding and dissociation kinetics to Aurora A at 25 °C. Binding kinetics was monitored by stopped-flow fluorescence at different concentrations of AT9283 (indicated) to 0.5 μM Aurora A. Dissociation kinetics were obtained for fully equilibrated drug/kinase complex (k obs,off ) or for the initial encounter complex (k off,djump ) by using a 1 hour or a short 2 s incubation of the kinase with AT9283, respectively, before inducing dissociation by a buffer wash using Creoptix WAVE waveguide interferometry. Global fitting was performed with KinTek Explorer software using the model in Figure 7H (reduced χ 2 = 3.2). Fluorescence traces are the average of at least five replicate measurements (n > 5). Alternative binding models of AT9283 to Aurora A cannot explain the experimental data. (A) Our initial three-state binding scheme, where AT9283 binds only the DFG in state of Aurora A and is followed by an induced-fit step, is incorrect. The best global fit (shown in red) did not describe the data as can be seen by visual inspection and from the reduced χ 2 value of 36. (B) An alternative model, where AT9283 can bind to Aurora A irrespective of the state of the DFG-loop, and binding is followed by an induced-fit step did not result in adequate fits (data not shown) and a reduced χ 2 value of 52. In both cases the values for the interconversion between AurA out and AurA in were taken from the Gleevec experiment ( Figure 5-figure supplement 2) . Fluorescence traces are the average of at least five replicate measurements (n > 5). 
Data collection and refinement statistics for dephosphorylated Aurora
